- DIATER presented its advances in molecular immunotherapy at EAACI 2026, held from 12 to 15 June 2026
- Its immersive stand in Istanbul reflected DIATER’s commitment to advancing the field of allergology
- Scientific communications and posters reinforced DIATER’s research commitment to driving progress in molecular immunotherapy
DIATER participates in EAACI 2026, one of the leading international meetings in allergology
From 12 to 15 June, DIATER took part in the Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2026, held in Istanbul, Turkey. As in the previous year, the company participated in this key international meeting for allergology and clinical immunology, reaffirming its commitment to research, innovation and scientific progress..
DIATER’s participation in EAACI 2026 provided another opportunity to share knowledge, connect with healthcare professionals from around the world and showcase the company’s work in allergen-based immunotherapy, aimed at contributing to the future of the diagnosis and treatment of allergic diseases.
Reflecting more than 25 years of developing innovative solutions for patients with allergies, DIATER purifies molecular allergens from allergenic extracts of Alternaria alternata, Cupressus arizonica and Dermatophagoides pteronyssinus, which are used in molecular immunotherapy. Allergen Servilab, a DIATER Group company specialising in the production of raw materials, applies stringent quality controls to help make state- of-the-art diagnostic and treatment solutions available to patients with allergies.
A modern, immersive stand bringing science closer to healthcare professionals
The DIATER team during the EAACI 2026 Congress in Istanbul, Turkey
At this year’s congress, DIATER featured a modern, immersive stand designed as a meeting point for science, innovation and experience. Through this environment, the company presented its vision of contemporary allergology and its commitment to solutions based on precision medicine.
The stand gave healthcare professionals the opportunity to learn more about DIATER’s advances in molecular immunotherapy, an area of work focused on improving the management of allergic diseases and continuing to develop scientific tools to support specialists.
Research, scientific communications and the future of immunotherapy
DIATER showcases its commitment to innovation in allergology at EAACI 2026
During the congress, DIATER contributed to the EAACI 2026 scientific programme through the presentation of scientific communications and posters, reflecting its commitment to research excellence and to advancing knowledge in the field of allergology.
These developments form part of DIATER’s goal of continuing to advance immunotherapy based on purified allergens and new molecular approaches that can help improve patients’ lives. Through its participation in EAACI 2026, DIATER continues to move forward alongside the scientific community towards the future of the diagnosis and treatment of allergic diseases.
